With the development of artificial intelligence technology, it plays an important role in laboratory medicine, especially in the automatic identification of cell morphology. The new generation of AI technology shows the characteristics of deep learning, autonomous learning, human-machine collaboration, and so on.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

BioMérieux said Friday it is seeking US Food and Drug Administration 510(k) clearance that would allow a US launch of its Vitek Reveal rapid antimicrobial susceptibility testing system to help guide treatment of bacterial sepsis.

The US Department of Health and Human Services' Biomedical Advanced Research Development Authority (BARDA) this week issued a solicitation for proposals for the research and development of immune assays to evaluate responses to COVID-19 vaccines.

Evident Corporation announced that it has been acquired by private equity firm Bain Capital Private Equity from Olympus Corporation pursuant to the definitive agreement signed on August 29, 2022.

In the afternoon of March 30, the first batch of hospitals of the International Hospital Accreditation and Certification Standards (China) accreditation and certification kick-off meeting was held in Qianhai, Shenzhen.

A study of infants in the neonatal intensive care unit in China investigated whether those conceived with assistance had more genetic diagnoses or de novo mutations.

The Berlin, Germany-based firm developed an assay for Marburg virus on its Minoo portable isothermal molecular diagnostic system.

Chinese immunodiagnostics market has maintained an overall growth rate of approximately 20% over the past five years, and is expected to reach a market size of CNY 52.4 billion in 2022.

Danaher subsidiary Leica Biosystems said Monday that it secured US Food and Drug Administration 510(k) clearance for its Bond MMR Antibody Panel to help identify potential Lynch syndrome in colorectal cancer patients.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round.